Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Preferred Stock Liabilities: 2020

  • Caribou Biosciences' Preferred Stock Liabilities was N/A to $41.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $41.3 million, marking a year-over-year change of. This contributed to the annual value of $41.3 million for FY2020, which is N/A change from last year.
  • According to the latest figures from Q4 2020, Caribou Biosciences' Preferred Stock Liabilities is $41.3 million.
  • Over the past 5 years, Caribou Biosciences' Preferred Stock Liabilities peaked at $41.3 million during Q4 2020, and registered a low of $41.3 million during Q4 2020.
  • Moreover, its 1-year median value for Preferred Stock Liabilities was $41.3 million (2020), whereas its average is $41.3 million.